D. Western Therapeutics Institute, Inc.
Stock Price Chart
2026/08/03 UpdatedPrice Trend
2026/08/03 UpdatedPrice & Trading Details
2026/08/03 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/02 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥448M | ¥428M | ¥472M | ¥388M |
| Gross Profit | ¥421M | ¥392M | ¥425M | ¥349M |
| Operating Income | -¥306M | -¥799M | -¥1,210M | -¥620M |
| Pretax Income | -¥437M | -¥824M | -¥1,283M | -¥622M |
| Net Income | -¥430M | -¥812M | -¥1,290M | -¥632M |
| EPS | -¥14.50 | -¥25.56 | -¥36.74 | -¥13.19 |
| Operating Margin | -68.27% | -186.42% | -256.50% | -159.92% |
| Balance Sheet | ||||
| Total Assets | ¥2,956M | ¥2,373M | ¥1,669M | ¥2,169M |
| Total Equity | ¥1,857M | ¥1,280M | ¥734M | ¥1,435M |
| Total Liabilities | ¥1,099M | ¥1,094M | ¥936M | ¥734M |
| Cash | ¥2,335M | ¥1,867M | ¥1,126M | ¥1,710M |
| Interest-bearing Debt | ¥968M | ¥885M | ¥798M | ¥605M |
| Equity Ratio | 62.83% | 53.92% | 43.96% | 66.17% |
| D/E Ratio | 0.52 | 0.69 | 1.09 | 0.42 |
| Cash Flow | ||||
| Operating CF | -¥355M | -¥587M | -¥1,299M | -¥494M |
| Investing CF | -¥140M | -¥15M | -¥10M | -¥2M |
| Financing CF | ¥867M | ¥134M | ¥568M | ¥1,080M |
| Free CF | -¥365M | -¥602M | -¥1,309M | -¥497M |
| Efficiency | ||||
| ROE | -23.13% | -63.48% | -175.82% | -44.03% |
| ROA | -14.53% | -34.23% | -77.29% | -29.14% |
Latest IR Information
-
Notice on Monthly Exercise Status of the 13th Stock Acquisition Rights (with Exercise Price Adjustment Clause)
Publish the monthly exercise status for the 13th stock acquisition rights (with exercise price adjustment clause) issued on July 31, 2025, for July 2026. Granted shares: 76,000 shares; exercised stock acquisition rights: 760 units; exercise ratio: 0.17%; unexercised: 9,098 shares...
Read more -
Notice of Changes to a Debt Agreement with Financial Covenants
Hedging covenants attached loan agreement amended. Targets are the revolving loan agreements dated April 16, 2010 and June 30, 2022. Changes: keep equity attributable to owners at positive amounts at each fiscal year-end, hold fixed deposits exceeding loan balances. Impact...
Read more -
Regarding the U.S. Sales Partnership and Launch Schedule for Bondlido
Read more -
Notice of Monthly Exercise Status of the 13th Stock Acquisition Rights (with Exercise Price Adjustment Clause)
Read more
Latest News (5 items)
Company Information
About
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; and DWR-2206, a regenerative medicine cell-product for bullous keratopathy. D. Western Therapeutics Institute, Inc. was founded in 1999 and is headquartered in Nagoya, Japan.
